Hormonal
GLP-1 receptor agonists (specifically semaglutide and tirzepatide) significantly improve cardiovascular outcomes, symptoms, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, primarily through substantial weight loss and metabolic improvement.
If you have HFpEF and are obese, GLP-1 medications like semaglutide or tirzepatide are now proven to help your heart, reduce symptoms, and improve your quality of life. The key is that this is intentional weight loss, which is different from the involuntary weight loss seen in advanced heart failure. Discuss these options with your cardiologist, as they can significantly reduce your risk of hospitalization and cardiovascular death.
The STEP-HFpEF trials for the first time provided clear evidence that managing excess weight in HFpEF can be transformative. Those in the treatment arm achieved significant weight loss and improvement in quality of life, symptoms, and functional capacity, with no increased risk... The SUMMIT trial... demonstrated that in HFpEF and BMI > 30 kg/m2, tirzepatide use was associated with not only improved quality of life but also cardiovascular outcomes, with reduced occurrence of cardiovascular death or worsening heart-failure event.
Why this rating
Based on recent, large-scale randomized controlled trials (STEP-HFpEF, SUMMIT) with clear positive outcomes.
Source
Obesity and heart failure: exploring the cardiometabolic axis
Jennifer J. Rayner et al. · Cardiovascular Research · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →